Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Tuberculosis (TB) control is hampered by drug-resistant TB (DR-TB) in tropical and subtropical regions, threatening the WHO's End TB Strategy.
• Emergence of DR-TB is driven by mutations in the Mycobacterium tuberculosis (MTB) strain, complicating treatment and increasing costs.
• Traditional treatment approaches face challenges due to pathogen evolution and the need for novel therapeutic strategies.

Purpose of the Study:

• To review current progress and challenges in the treatment of drug-resistant tuberculosis.
• To summarize antitubercular compounds in development for DR-TB and host-directed therapies.
• To highlight issues in DR-TB diagnosis, treatment regimens, and drug discovery impacting treatment outcomes.

Main Methods:

• Literature review of current research on DR-TB treatment.
• Summary of antitubercular compounds in preclinical and clinical development.
• Analysis of challenges in DR-TB diagnosis and therapeutic strategies.

Main Results:

• Several novel antitubercular agents targeting existing and new pathways are under investigation.
• Host-directed therapies and immunotherapies show promise in reducing pathogen drug susceptibility.
• Significant challenges persist in DR-TB diagnosis, treatment adherence, and drug discovery.

Conclusions:

• Advancements in antitubercular compounds and host-directed therapies offer new avenues for DR-TB treatment.
• Addressing diagnostic and treatment regimen challenges is crucial for improving patient outcomes and achieving TB elimination goals.
• Continued research and development are essential to overcome the complexities of drug-resistant tuberculosis.